Aetna, a CVS Health Company

aetna.com

Here at Aetna, a CVS Health business, we are building a healthier world by making healthcare easy, affordable and all about you. Follow our LinkedIn page for company news, industry commentary, jobs and more. Founded in 1853 in Hartford, CT, Aetna is one of the nation's leading diversified health care benefits companies, serving an estimated 46.7 million people with information and resources to help them make better decisions about their healthcare.

Related News

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

news image

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More

MEDTECH

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

news image

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

MEDTECH

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

news image

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More
news image

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More
news image

MEDTECH

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

MEDTECH

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More